|
COPYRIGHT 2004 International Medical News Group
SAN ANTONIO -- The older generation osteoporosis drug, strontium ranelate, is receiving renewed attention as a result of a metaanalysis showing that it reduces fracture rates in postmenopausal women as well as bisphosphonates do.
Like bisphosphonates, strontium ranelate inhibits bone resorption but also increases bone formation, a combination that improves bone density and bone mass. Jean-Yves Reginster, M.D., said at the annual meeting of the American College of Rheumatology.
In one of the...
Read the full article for free courtesy of your local library.
| 
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
